BAIWANG CO (06657) plans to repurchase company shares for a total amount not exceeding 1.05 billion Hong Kong dollars.
Baiwang Group (06657) announced that on June 26, 2026, the board of directors approved the company to repurchase H shares in the public market of Hong Kong Stock Exchange within the authorized repurchase range, depending on market conditions and the actual situation of the company, with a total repurchase amount not exceeding HK$105 million (or equivalent foreign currency). The actual number of H shares repurchased shall not exceed the number of H shares that can be repurchased under the repurchase authorization. The implementation period of the H share repurchase shall be from June 26, 2026 to June 25, 2027 (inclusive), but shall not exceed the expiration date of the repurchase authorization. The repurchased H shares will be cancelled or held as treasury shares.
BAIWANG CO (06657) announced that on June 26, 2026, the board of directors approved the company to repurchase H shares in the public market of the Stock Exchange of Hong Kong within the authorized amount, based on market conditions and the actual situation of the company. The total amount of the repurchase shall not exceed HKD 105 million (or equivalent foreign currency). The actual number of H shares repurchased shall not exceed the number of H shares that can be repurchased under the authorization. The implementation period of the H share repurchase shall be from June 26, 2026, to June 25, 2027 (inclusive), but shall not exceed the expiration date of the repurchase authorization. The repurchased H shares will be cancelled or held as treasury shares.
Related Articles

Lebang Pharmaceutical-B (09637) public offering received nearly a thousand times oversubscribed and will debut on the Hong Kong Stock Exchange on June 29.

KINGWISOFT TECH (08295) appoints Tian Wenyu and Jiang Ning as independent non-executive directors.

KINGWISOFT TECH (08295) announces annual performance, with a loss of approximately 148 million yuan attributable to owners, a year-on-year decrease of 28.58%.
Lebang Pharmaceutical-B (09637) public offering received nearly a thousand times oversubscribed and will debut on the Hong Kong Stock Exchange on June 29.

KINGWISOFT TECH (08295) appoints Tian Wenyu and Jiang Ning as independent non-executive directors.

KINGWISOFT TECH (08295) announces annual performance, with a loss of approximately 148 million yuan attributable to owners, a year-on-year decrease of 28.58%.

RECOMMEND





